CD274 and neoplasm: For squamous NSCLC in IMpower131,15 PFS in the high PD‐L1 (PD‐L1 expression of tumor cell (TC) or immune cell (IC), (TC3 or IC3)) group benefited more from the combination therapy than the low (TC1/2 or IC1/2) or negative (TC0 and IC0) groups (Table 1).